A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59® -adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects

Journal of Preventive Medicine and Hygiene

Volumn 53, Issue 3, 2012, Pages 136-142

  Czajka, H ^a   Unal S ^b   Ulusoy, S ^c   Usluer, G ^d   Strus, A ^e   Sennaroglu, E ^f   Guzik, J ^g   Topeli Iskit, A ^b   Dargiewicz, A ^h   Musial, D ⁱ   Caylan, R ^j   Dziduch, J ^k   Eskioglu, E ^f   Hasiec, B ⁱ   Cwinarowiczliwa, E ^l   Belli, R ^m   Abdel Messih, I A ^m   Beygo, J ^m   Fragapane, E ^m  

^a Provincial Children's Specialized Hospital   (Poland)

^b HACETTEPE UNIVERSITY   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d Department of Infectious Diseases and Clinical Microbiology   (Turkey)

^e Medical Center Family Medicine   (Poland)

^f Sample Training and Research Hospital Ankara   (Turkey)

^g Hospital of Internal Clinical Pharmacology Research Center Monipol   (Poland)

^h NZOZ Centrum Medyczne   (Poland)

ⁱ NZOZ Center for Medical Genetics   (Poland)

^j ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^k Independent Public Health Care Centre   (Poland)

^l Non Public Health Care Centre   (Poland)

^m NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

more..

Author keywords

Adjuvant; H5N1; Influenza; MF59; Pandemic

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; MIFAMURTIDE;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHEMA; EUROPE; FATIGUE; FEMALE; GROUPS BY AGE; HEMAGGLUTINATION; HEMOLYSIS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE FACTORS; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; POLYSORBATES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84868124432     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gambotto A, Barratt-Boyes SM, de Jong MD, et al. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008;371:1464-75. (Pubitemid 351618340)
2. Jennings LC, Monto AS, Chan PK, et al. Stockpiling prepan-demic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008;8:650-8.
3. Rockman S, Brown L. Pre-pandemic and pandemic influenza vaccines. Hum Vaccin 2010;6:792-801.
4. Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet 2006;367:1405-11.
5. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503.
6. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2:197-203.
7. Atmar RL, Keitel WA, Patel SM, et al. Safety and immuno-genicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43:1135-42. (Pubitemid 44632795)
8. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:699-710. (Pubitemid 47607847)
9. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687-93. (Pubitemid 36287599)
10. Sambhara S, Poland GA. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Annu Rev Med 2010;61:187-98.
11. Singh N, Pandey A, Mittal SK. Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med 2010;12:e14.
12. Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011;7:539-48.
13. Tsai TF, Crucitti A, Nacci P, et al. Explorations of clinical trials and pharmacovigilance databases of MF59((R))-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011.
14. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177-84. (Pubitemid 36438758)
15. Gasparini R, Pozzi T, Montomoli E, et al. Increased immuno-genicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-40. (Pubitemid 32900039)
16. Minutello M, Senatore F, Cecchinelli G, et al. Safety and im-munogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17:99-104. (Pubitemid 28494106)
17. Nicholson KG, Colegate AE, Podda A, et al. Safety and an-tigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43. (Pubitemid 32568336)
18. Schild GC, Pereira MS, Chakraverty P. Single-radial-hemoly-sis: a new method for the assay of antibody to influenza hae-magglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975;52:43-50.
19. Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004;4:499-509. (Pubitemid 39077920)
20. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006;442:448-52. (Pubitemid 44264793)
21. Poland GA. Vaccines against avian influenza-a race against time. N Engl J Med 2006;354:1411-3.
22. Bresson JL, Perronne C, Launay O, et al. Safety and im-munogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-64. (Pubitemid 43744370)
23. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006;368:991-7. (Pubitemid 44353667)
24. World Health Organization.WHO Global Pandemic Preparedness Plan. 2007: http://www.who.int/entity/csr/resources/publi-cations/influenza/ StregPlanEPR-GIP-2006-2.pdf.
25. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006;194(Suppl. 2):S111-8. (Pubitemid 44630954)
26. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011;203:1729-38.
27. Liu WM. Aging and impaired immunity to influenza viruses: Implications for vaccine development. Hum Vaccin 2011;7:94-8.
28. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005;23(Suppl. 1):S10-25.
29. Vesikari T, Karvonen A, Tilman S, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010;126:e762-70.
30. Fragapane E, Gasparini R, Schioppa F, et al. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 2010;17:1817-9.
31. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvant-ed H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009;4:e4384.
32. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008;359:1631-3.
33. Note for guidance on harmonization of requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products, London, United Kingdom. 1997: http://www. emea.europa.eu/docs/en-GB/document-library/ Scientific- guideline/2009/09/WC500003945.pdf.
34. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009;106:7962-7.